{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:10:47Z","timestamp":1784679047071,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>MiR-125 has been shown to be involved in a variety of cancers, including cervical cancer (CC). Here, our goal was to explore miR-125 functional role and molecular mechanism in cervical cancer development and progression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>qRT-PCR was employ to detect miR-125 and VEGF mRNA expression. Western blot was applied for testing protein levels (VEGF, E-cadherin, N-cadherin, vimentin, AKT, p-AKT, PI3K, and p-PI3K). MTT and transwell assays were used for detecting cervical cancer cell progression, including cell viability, migration, and invasion.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We observed that miR-125 was downregulated, whereas VEGF was upregulated in cervical cancer tissues and cell lines (CaSki and SiHa). MiR-125 inhibited the proliferation, invasion, and migration by targeting VEGF in cervical cancer. Moreover, miR-125 negatively regulated VEGF expression in cervical cancer tissues. Finally, we demonstrated that miR-520d-5p inhibited the activation of PI3K\/AKT signaling pathway.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In conclusion, the findings demonstrated that miR-125 inhibited cervical cancer progression and development by suppression VEGF and PI3K\/AKT signaling pathway.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12957-020-01881-0","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T14:05:11Z","timestamp":1590847511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"18","author":[{"given":"Ke","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"1881_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1881_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2217\/fon.10.38","volume":"6","author":"P Laukkanen","year":"2010","unstructured":"Laukkanen P, Laara E, Koskela P, Pukkala E, Virkkunen H, Lehtinen M. Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses. Future Oncol. 2010;6:709\u201316.","journal-title":"Future Oncol"},{"key":"1881_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1634\/theoncologist.2013-0123","volume":"18","author":"S Li","year":"2013","unstructured":"Li S, Hu T, Lv W, Zhou H, Li X, Yang R, Jia Y, Huang K, Chen Z, Wang S, et al. Changes in prevalence and clinical characteristics of cervical cancer in the People\u2019s Republic of China: a study of 10,012 cases from a nationwide working group. Oncologist. 2013;18:1101\u20137.","journal-title":"Oncologist"},{"key":"1881_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ijc.30468","volume":"140","author":"HK Holt","year":"2017","unstructured":"Holt HK, Zhang L, Zhao FH, Hu SY, Zhao XL, Zhang X, Pan QJ, Zhang WH, Smith JS, Qiao YL. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China. Int J Cancer. 2017;140:544\u201354.","journal-title":"Int J Cancer"},{"key":"1881_CR5","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1881_CR6","doi-asserted-by":"crossref","unstructured":"Reddy, Kaladhar B: MicroRNA (miRNA) in cancer. Cancer Cell International, 15:38.","DOI":"10.1186\/s12935-015-0185-1"},{"key":"1881_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13046-017-0617-y","volume":"36","author":"P Dong","year":"2017","unstructured":"Dong P, Xiong Y, Hanley SJB, Yue J, Watari H. Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation. J Exp Clin Cancer Res. 2017;36:150.","journal-title":"J Exp Clin Cancer Res"},{"key":"1881_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-015-0385-2","volume":"14","author":"G Shishodia","year":"2015","unstructured":"Shishodia G, Shukla S, Srivastava Y, Masaldan S, Mehta S, Bhambhani S, Sharma S, Mehrotra R, Das BC, Bharti AC. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Mol Cancer. 2015;14:116.","journal-title":"Mol Cancer"},{"key":"1881_CR9","doi-asserted-by":"publisher","first-page":"E230","DOI":"10.1002\/ijc.29160","volume":"136","author":"H Xie","year":"2015","unstructured":"Xie H, Lee L, Scicluna P, Kavak E, Larsson C, Sandberg R, Lui WO. Novel functions and targets of miR-944 in human cervical cancer cells. Int J Cancer. 2015;136:E230\u201341.","journal-title":"Int J Cancer"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1476-4598-9-167","volume":"9","author":"SM Wilting","year":"2010","unstructured":"Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, Steenbergen RD. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.","journal-title":"Mol Cancer"},{"key":"1881_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/0008-5472.CAN-09-3289","volume":"70","author":"X Hu","year":"2010","unstructured":"Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010;70:1441\u20138.","journal-title":"Cancer Res"},{"key":"1881_CR12","doi-asserted-by":"crossref","unstructured":"Wang YF, Yang HY, Shi XQ, Wang Y. Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer. Cancer Biol Ther. 2018:1\u201312.","DOI":"10.1080\/15384047.2018.1491497"},{"key":"1881_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1186\/s12885-018-4590-4","volume":"18","author":"B Pardini","year":"2018","unstructured":"Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A. MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer. 2018;18:696.","journal-title":"BMC Cancer"},{"key":"1881_CR14","doi-asserted-by":"publisher","first-page":"i8","DOI":"10.1093\/annonc\/mdz029.017","volume":"30","author":"O.G. Trifanescu","year":"2019","unstructured":"Trifanescu OG, Topliceanu F, Gusoiu BA, Gales LN, Anghel R. 24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients. Ann Oncol. 2019;30.","journal-title":"Annals of Oncology"},{"key":"1881_CR15","doi-asserted-by":"crossref","unstructured":"Vidal J, Bellosillo B, Santos Vivas C, Garcia-Alfonso P, Carrato A, Cano MT, Garcia-Carbonero R, Elez E, Losa F, Massuti B, et al. Ultra-selection of metastatic colorectal cancer patients using next generation sequencing to improve clinical efficacy of anti-EGFR therapy. Ann Oncol. 2019.","DOI":"10.1093\/annonc\/mdy149.005"},{"key":"1881_CR16","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1038\/s41467-018-05982-z","volume":"9","author":"T Liu","year":"2018","unstructured":"Liu T, Ma W, Xu H, Huang M, Zhang D, He Z, Zhang L, Brem S, O'Rourke DM, Gong Y, et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat Commun. 2018;9:3439.","journal-title":"Nat Commun"},{"issue":"432","key":"1881_CR17","doi-asserted-by":"publisher","first-page":"eaag0945","DOI":"10.1126\/scitranslmed.aag0945","volume":"10","author":"Joao Incio","year":"2018","unstructured":"Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018;10.","journal-title":"Science Translational Medicine"},{"key":"1881_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1470-2045(17)30514-4","volume":"18","author":"S Delaloge","year":"2017","unstructured":"Delaloge S, DeForceville L. Targeting PI3K\/AKT pathway in triple-negative breast cancer. Lancet Oncol. 2017;18:1293\u20134.","journal-title":"Lancet Oncol"},{"key":"1881_CR19","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J Clin Oncol. 2016;34:3803\u201315.","journal-title":"J Clin Oncol"},{"key":"1881_CR20","first-page":"513","volume":"23","author":"N Xia","year":"2019","unstructured":"Xia N, Tan WF, Peng QZ, Cai HN. MiR-374b reduces cell proliferation and cell invasion of cervical cancer through regulating FOXM1. Eur Rev Med Pharmacol Sci. 2019;23:513\u201321.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1881_CR21","first-page":"131","volume":"31","author":"F Wang","year":"2016","unstructured":"Wang F, Li B, Xie X. The roles and clinical significance of microRNAs in cervical cancer. Histol Histopathol. 2016;31:131\u20139.","journal-title":"Histol Histopathol"},{"key":"1881_CR22","first-page":"374924","volume":"2015","author":"M Diaz-Gonzalez Sdel","year":"2015","unstructured":"Diaz-Gonzalez Sdel M, Deas J, Benitez-Boijseauneau O, Gomez-Ceron C, Bermudez-Morales VH, Rodriguez-Dorantes M, Perez-Plasencia C, Peralta-Zaragoza O. Utility of microRNAs and siRNAs in cervical carcinogenesis. Biomed Res Int. 2015;2015:374924.","journal-title":"Biomed Res Int"},{"key":"1881_CR23","doi-asserted-by":"crossref","unstructured":"Wu S, Shen W, Yang L, Zhu M, Zhang M, Zong F, Geng L, Wang Y, Huang T, Pan Y, et al. Genetic variations in miR-125 family and the survival of non-small cell lung cancer in Chinese population. Cancer Med. 2019.","DOI":"10.1002\/cam4.2073"},{"key":"1881_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1053\/j.gastro.2018.06.030","volume":"155","author":"L Mari","year":"2018","unstructured":"Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM. Hulshof M, et al: microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients. Gastroenterology. 2018;155:784\u201398.","journal-title":"Gastroenterology"},{"key":"1881_CR25","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-018-30942-4","volume":"8","author":"M Yuan","year":"2018","unstructured":"Yuan M, Da Silva A, Arnold A, Okeke L, Ames H, Correa-Cerro LS, Vizcaino MA, Ho CY, Eberhart CG, Rodriguez FJ. MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep. 2018;8:12506.","journal-title":"Sci Rep"},{"key":"1881_CR26","doi-asserted-by":"publisher","first-page":"345080","DOI":"10.1155\/2015\/345080","volume":"2015","author":"H Chen","year":"2015","unstructured":"Chen H, Xu Z. Hypermethylation-associated silencing of miR-125a and miR-125b: a potential marker in colorectal cancer. Dis Markers. 2015;2015:345080.","journal-title":"Dis Markers"},{"key":"1881_CR27","doi-asserted-by":"crossref","unstructured":"Solecki G, Osswald M, Weber D, Glock M, Ratliff M, Muller HJ, Krieter O, Kienast Y, Wick W, Winkler F. Differential effects of Ang-2\/VEGF-A inhibiting antibodies in combination with radio- or chemotherapy in glioma. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11030314"},{"key":"1881_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-019-1045-y","volume":"38","author":"V Ciccone","year":"2019","unstructured":"Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L, Ziche M. Correction to: stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid\/HIF-1alpha\/VEGF signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res. 2019;38:45.","journal-title":"J Exp Clin Cancer Res"},{"key":"1881_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-017-0620-0","volume":"16","author":"L Liu","year":"2017","unstructured":"Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W, Li L, Zhang W, Shi S, Song Y, Wang L. MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol Cancer. 2017;16:50.","journal-title":"Mol Cancer"},{"key":"1881_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-4598-14-5","volume":"14","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Zhang Y, Sun XX, Ma X. Chen ZN: microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer. 2015;14:5.","journal-title":"Mol Cancer"},{"key":"1881_CR31","first-page":"665","volume":"42","author":"QB Wu","year":"2018","unstructured":"Wu QB, Chen J, Zhu JW, Yin X, You HY, Lin YR, Zhu HQ. MicroRNA125 inhibits RKO colorectal cancer cell growth by targeting VEGF. Int J Mol Med. 2018;42:665\u201373.","journal-title":"Int J Mol Med"},{"key":"1881_CR32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC. AKT\/PKB signaling: navigating downstream. Cell. 2007;129:1261\u201374.","journal-title":"Cell"},{"key":"1881_CR33","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.ctrv.2014.09.005","volume":"40","author":"H Stegeman","year":"2014","unstructured":"Stegeman H, Span PN, Kaanders JH, Bussink J. Improving chemoradiation efficacy by PI3-K\/AKT inhibition. Cancer Treat Rev. 2014;40:1182\u201391.","journal-title":"Cancer Treat Rev"},{"key":"1881_CR34","first-page":"1891","volume":"22","author":"F Wang","year":"2018","unstructured":"Wang F, Tan WH, Liu W, Jin YX, Dong DD, Zhao XJ, Liu Q. Effects of miR-214 on cervical cancer cell proliferation, apoptosis and invasion via modulating PI3K\/AKT\/mTOR signal pathway. Eur Rev Med Pharmacol Sci. 2018;22:1891\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1881_CR35","doi-asserted-by":"publisher","first-page":"28851","DOI":"10.18632\/oncotarget.4767","volume":"6","author":"JP Tsai","year":"2015","unstructured":"Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT, Hsieh YH. Licochalcone A induces autophagy through PI3K\/Akt\/mTOR inactivation and autophagy suppression enhances licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget. 2015;6:28851\u201366.","journal-title":"Oncotarget"},{"key":"1881_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/IGC.0000000000000474","volume":"25","author":"E Jiang","year":"2015","unstructured":"Jiang E, Sun X, Kang H, Sun L, An W, Yao Y, Hu X. Dehydrocostus lactone inhibits proliferation, antiapoptosis, and invasion of cervical cancer cells through PI3K\/Akt signaling pathway. Int J Gynecol Cancer. 2015;25:1179\u201386.","journal-title":"Int J Gynecol Cancer"},{"key":"1881_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1158\/1078-0432.CCR-11-2485","volume":"18","author":"JK Schwarz","year":"2012","unstructured":"Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW. Pathway-specific analysis of gene expression data identifies the PI3K\/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012;18:1464\u201371.","journal-title":"Clin Cancer Res"},{"key":"1881_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1568009611313020004","volume":"13","author":"J Wu","year":"2013","unstructured":"Wu J, Chen C, Zhao KN. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 2013;13:143\u201356.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T23:09:50Z","timestamp":1622329790000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01881-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"7 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}